In non-DM patients, P2Y12 inhibitor monotherapy showed a great reduction in bleeding events (OR: 0.58, 95% CI: 0.38–0.88, p = 0.01, I2 = 78%, PHeterogeneity = 0.004). Here, P2RY12 is linked to diabetes mellitus.